Ovarian Cancer Clinical Trials & Research

Doctors at Memorial Sloan Kettering are constantly working to improve treatment for ovarian cancer through clinical trials. Participating in a clinical trial may give you access to treatments that are not widely available elsewhere, and may offer additional options if your cancer has returned after standard treatment.

Our doctors lead clinical trials that test new drugs and drug combinations, surgical approaches, and strategies for preserving quality of life during and after treatment. We can help determine which clinical trials are right for you.

The following clinical trials for ovarian cancer are currently enrolling new patients. To learn more about a particular study, choose from the list below.

and/or
27 Clinical Trials found
A Phase 1 Study of BMS-986500 in People With Advanced Solid Tumors
Researchers are seeking the best dose of BMS-986500 to give alone and with other drugs in people with solid tumors. The people in this study have ovarian, endometrial, gastroesophageal, or breast cancer. Their tumors have spread beyond their original locations.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of CTIM-76 in People With Advanced Ovarian or Endometrial Cancer
Researchers want to find the best dose of CTIM-76 to treat advanced ovarian or endometrial cancer. The people in this study have ovarian or endometrial cancer that makes a protein called CLDN6. This protein may fuel cancer growth.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of LY4170156 in People With Solid Tumors
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of NT-175 in People With Advanced Solid Tumors
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer
Researchers want to find the best dose of VLS-1488 to treat various types of advanced cancer. VLS-1488 blocks KIF18A, a protein that plays a role in the rapid growth of cancer cells. By blocking KIF18A, VLS-1488 may cause cancer cells to stop growing and die. VLS-1488 is taken orally (by mouth).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1a Study of AVA6000 in People with Solid Tumors
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1a Study of CUSP06 in People With Ovarian or Endometrial Cancer
Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b-2 Study of COM701 as Maintenance Therapy in People With Recurrent Ovarian Cancer
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b-2 Study of Raludotatug Deruxtecan in People With Ovarian Cancer
Researchers are seeking the best dose of raludotatug deruxtecan (R-DXd) for people with ovarian cancer when given with standard chemotherapy. The people in this study have ovarian cancer that came back after chemotherapy that included a platinum-containing drug.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau